No Data
Is Shanghai Junshi Biosciences (HKG:1877) Using Too Much Debt?
Junshi Biotech: Junshi Biotech 2024 Annual Performance Report Announcement
Junshi Biotech 2024 Annual Results Report Announcement
JUNSHI BIO: INSIDE INFORMATION -2024 PRELIMINARY RESULTS
JUNSHI BIO (688180.SH): Net loss of 1.28 billion yuan in 2024.
On February 27, Gelonghui reported that JUNSHI BIO (688180.SH) announced its 2024 annual performance preliminary report, with total revenue of 1,948.3173 million yuan, an increase of 29.67% year-on-year, and a net income attributable to the parent company's owners of -1,282.2792 million yuan. During the reporting period, the company's revenue increased mainly due to the sales revenue of commercialized Pharmaceuticals compared to the same period last year. By the end of the reporting period, the company had already owned Trepulimab injection (trade name: Tuoyi), Adalimumab injection (trade name: Junmaikang), Dextromethorphan hydrobromide tablets (trade name: Mindewei), and Angorin.
Express News | Junshi Biosciences Prelim 2024 Net Loss at 1.3 Bln Yuan
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
